Predictors of the results of radioiodine therapy of Gagves’ disease
https://doi.org/10.14341/ket20106348-53
Abstract
The aim of this study was to investigate different clinical and laboratory predictors influence on radioiodine therapy results for Graves' disease. A 1-year prospective study was performed on 621 patients treated with empirical radioiodine therapy. Mean administered dose of 131I was 350 MBq. All patients were divided into two groups with small (<25 ml) and large (>25 ml) thyroid gland volume. One day before radioiodine therapy all patients were examined with fT4 measurement and radioiodine uptake test to determine percentage uptake at 2 h, 4 h, and 24 h after test dose of 131I administration. Unique universal method to estimate predictors influence for any classification task was presented and used for actual task of radioiodine therapy results estimation. For patients with small thyroid gland volume a set of 11 predictors that have an influence on therapy result was revealed and importance of each predictor from indicated set was determined. The most influential predictors were administered dose of 131I, thyroid gland volume, percentage uptake at 24 h after test dose of 131I administration, and patient age. For patients with large thyroid gland volume a set of 10 predictors was revealed. The most influential predictors were administered dose of 131I, thyroid gland volume, percentage uptake at 2 h after test dose of 131I administration, and patient age. Accounting all predictors from indicated sets for both patient groups allows constructing of classification system that provides therapy result estimation for any patient and any administered dose of 131I with accuracy above 90%.
References
1. Ефимов А.С. Решение задачи кластеризации методом конкурентного обучения при неполных статистических данных // Вест. Нижегор. госун-та им. Н.И. Лобачевского. Информационные технологии. 2010. №1. С. 220–225.
2. Ефимов А.С. Гибридный иммунный алгоритм оптимизации нечетких систем TSK 0-порядка / Матер. конф. “Технологии Microsoft в теории и практике программирования – 2009”. Н. Новгород: Нижегор. госун-та. 2009. С. 143–150.
3. Farrar J.J., Toft A.D. Iodine-131 treatment of hyperthyroidism: Current issues // Clin. Endocrinol. 1991. V. 35. P. 207–212.
4. Imseis R.E., Vanmiddlesworth L., Massie J.D. et al. Pretreatment with propylthiouacil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism // J. Clin. Endocrinol. Metab. 1998. V. 83. P. 685–687.
5. Reiners C., Schneider P. Radioiodine therapy of thyroid autonomy // Eur. J. Nucl. Med. 2002. V. 29 (Suppl. 2). P. 471–478.
6. Andrade V.A., Gross J.L., Maia A.L. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study // J. Clin. Endocrinol. Metab. 2001. V. 86(8). P. 3488–3493.
7. Calegaro J.U., de Freitas Gomes E. et al. One-year follow-up of Graves’ disease treatment by four different protocols of radioiodine administration // Panminerva Med. 2000. V. 42(4). P. 241–245.
8. Sabri O., Zimny M., Schulz G. et al. Success rate of radioiodine therapy in Graves’ disease: the influence of thyrostatic medication // J. Clin. Endocrinol. Metab. 1999. V. 84(4). P. 1229–1233.
9. Nakazato N., Yoshida K., Mori K. et al. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves’ disease // Thyroid. 1999. V. 9(8). P. 775–779.
10. Sabri O., Schulz G., Zimny M. et al. Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves’ disease // Nuklearmed. 1998. V. 37(3). P. 83–89.
11. Braga M., Walpert N., Burch H.B. et al. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial // Thyroid. 2002. V. 12(2). P. 135–139.
12. Allahabadia A., Daykin J., Sheppard M.C. et al. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome // J. Clin. Endocrinol. Metab. 2001. V. 86(8). P. 3611–3617.
13. Bakker S.C., Zanin D.E., Zweers E.J. Treatment of hyperthyroidism caused by Graves’ disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose //Ned Tijdschr Geneeskd. 2002. V. 28. P. 1837–1841.
14. Chiovato L., Fiore E., Vitti P. et al. Outcome of thyroid function in Graves’ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodineinduced thyroid damage // J. Clin. Endocrinol. Metab. 1998. V. 83(1). P. 40–46.
15. Howarth D., Epstein M., Lan L. et al. Determination of the optimal minimum radioiodine dose in patients with Graves’ disease: a clinical outcome study // Eur. J. Nucl. Med. 2001. V. 28(10). P. 1489–1495.
16. Iagaru A., McDougall R.Treatment of thyrotoxicosis // J. Nucl. Med. 2007. V. 48(3). P. 379–389.
17. Kok S.W., Smit J.W., de Craen A.J. et al. Clinical outcome after standardized versus dosimetric radioiodine treatment of hyperthyroidism: an equivalence study // Nucl. Med. Commun. 2000. V. 21(11). P. 1071–1078.
18. Turner J., Sadler W., Brownlie B. et al. Radioiodine therapy for Graves’ disease: multivariate analysis of pretreatment parameters and early outcome // Eur. J. Nucl. Med. 1985. V. 11(6–7). P. 191–193.
Review
For citations:
, , , , Predictors of the results of radioiodine therapy of Gagves’ disease. Clinical and experimental thyroidology. 2010;6(3):48-53. (In Russ.) https://doi.org/10.14341/ket20106348-53
Views:
433
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
